United States · FDA National Drug Code directory
Simlandi
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 51759-386_021cc6a0-a2e6-4e30-95dc-065c64b7fe70
- Product NDC
- 51759-386
- Form
- KIT
- Composition / generic term
- adalimumab-ryvk
- Labeler
- Teva Pharmaceuticals USA, Inc.
- Marketing category
- BLA
- Marketing start / end (source format)
- 20250129
- Source listing expiry
- 20271231
Source-listed ingredients
Separate ingredient quantities are not available in this snapshot. Any composition term above is preserved as source text.
These values do not establish equivalence or a dose recommendation.
Packages
- 2 KIT in 1 CARTON (51759-386-22) / 1 KIT in 1 KIT * 1 SYRINGE in 1 TRAY / .2 mL in 1 SYRINGE (51759-497-31) * .4 mL in 1 POUCH (65517-0002-1) · 51759-386-22
Source and coverage
Open FDA National Drug Code directory →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse United States records →